BR112018013297A2 - composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo - Google Patents

composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo

Info

Publication number
BR112018013297A2
BR112018013297A2 BR112018013297-7A BR112018013297A BR112018013297A2 BR 112018013297 A2 BR112018013297 A2 BR 112018013297A2 BR 112018013297 A BR112018013297 A BR 112018013297A BR 112018013297 A2 BR112018013297 A2 BR 112018013297A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
salt
pyrazolone derivative
substituted bicyclic
preparing substituted
Prior art date
Application number
BR112018013297-7A
Other languages
English (en)
Chinese (zh)
Inventor
Lu Yun
Zhang Xinhua
Zhang Daimei
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of BR112018013297A2 publication Critical patent/BR112018013297A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a uma composição farmacêutica compreendendo um derivado de azo pirazolona biciclo-substituído ou um sal do mesmo e um método de preparação do mesmo. em particular, a composição farmacêutica divulgada na presente invenção compreende o ácido (z)-5-(2-hidroxi-3-(2-(3-metil-5-oxo-1-(5,6,7,8-tetra-hidronaftalen-2-il)-1h-pirazol-4(5h)-ilideno)hidrazino)fenil)furano-2-carboxílico ou um sal farmaceuticamente aceitável do mesmo, e pelo menos um agente de enchimento opcionalmente selecionado de celulose, celulose microcristalina, lactose e amido. a composição tem uma boa estabilidade, taxa de dissolução e biodisponibilidade, e o processo de preparação é simples, econômico e rápido.
BR112018013297-7A 2016-01-22 2017-01-16 composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo BR112018013297A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610046767 2016-01-22
CN201610046767.7 2016-01-22
PCT/CN2017/071219 WO2017124983A1 (zh) 2016-01-22 2017-01-16 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法

Publications (1)

Publication Number Publication Date
BR112018013297A2 true BR112018013297A2 (pt) 2018-12-11

Family

ID=59361374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013297-7A BR112018013297A2 (pt) 2016-01-22 2017-01-16 composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo

Country Status (13)

Country Link
US (1) US11116752B2 (pt)
EP (1) EP3375442A4 (pt)
JP (1) JP6913684B2 (pt)
KR (1) KR20180103056A (pt)
CN (2) CN112220766B (pt)
AU (1) AU2017209224A1 (pt)
BR (1) BR112018013297A2 (pt)
CA (1) CA3008036A1 (pt)
HK (1) HK1243359A1 (pt)
MX (1) MX2018008342A (pt)
RU (1) RU2733844C2 (pt)
TW (1) TW201726129A (pt)
WO (1) WO2017124983A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
CN101921232A (zh) * 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
CN102423485B (zh) * 2011-12-08 2014-08-06 赵联华 含有醋酸去氨加压素的口服组合物及其制备方法
CN104844582A (zh) 2015-04-24 2015-08-19 江苏恒瑞医药股份有限公司 一种血小板生成素模拟物的二乙醇胺盐的结晶形式及其制备方法

Also Published As

Publication number Publication date
EP3375442A1 (en) 2018-09-19
HK1243359A1 (zh) 2018-07-13
WO2017124983A1 (zh) 2017-07-27
US20190022065A1 (en) 2019-01-24
AU2017209224A1 (en) 2018-07-26
CN112220766B (zh) 2023-08-11
CN107249585A (zh) 2017-10-13
RU2018127922A (ru) 2020-02-25
TW201726129A (zh) 2017-08-01
CN112220766A (zh) 2021-01-15
RU2018127922A3 (pt) 2020-05-15
EP3375442A4 (en) 2018-12-26
KR20180103056A (ko) 2018-09-18
JP2019506371A (ja) 2019-03-07
JP6913684B2 (ja) 2021-08-04
CN107249585B (zh) 2020-12-08
MX2018008342A (es) 2019-01-31
CA3008036A1 (en) 2017-07-27
US11116752B2 (en) 2021-09-14
RU2733844C2 (ru) 2020-10-07

Similar Documents

Publication Publication Date Title
IL279688A (en) Heterocyclic and heteroaryl compounds for the treatment of Huntington&#39;s disease
BR112018015369A2 (pt) composição farmacêutica contendo inibidor de jak cinase ou sal farmaceuticamente aceitável do mesmo
MX2018009175A (es) Agonista fxr derivado de esteroides.
MX2018003357A (es) Proceso de compuesto antifungico.
BR112016007358A2 (pt) bloco bruto para usinagem de próteses dentárias
GEP20217227B (en) Novel phenyl derivatives
MX367358B (es) Composiciones farmaceuticas que comprenden azd9291.
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
CY1122352T1 (el) Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη
MX2017003943A (es) Producto farmaceutico.
MX2015016513A (es) Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.
MX2017017163A (es) Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.
MX2018006903A (es) Composicion farmaceutica.
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
JP2019041808A5 (pt)
JP2019041810A5 (pt)
PH12019502326A1 (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
PH12017501750A1 (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
IL289161A (en) Analogs of 3-(5-methyl-3,1-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide
JP2019041809A5 (pt)
BR112017013998A2 (pt) novos derivados de benzimidazol como agentes anti-histamínicos
PH12016500134A1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives
BR112018013297A2 (pt) composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo
BR112019003281A2 (pt) composição farmacêutica e métodos de usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements